| Clinical parameters |
Good
n (145 %) |
Poor
n (225 (60.8) |
Total
n (370 100.0) |
X2 |
Df |
P-value |
| Present BMI |
|
|
|
|
|
|
| Underweight |
3(16.7) |
15(83.3) |
18(100) |
|
|
|
| Normal |
94(45.2) |
114(54.8) |
208(100.0) |
|
|
|
| Overweight |
41(39.4) |
63(60.6) |
104(100) |
14.88 |
3 |
0.0019 |
| Obese |
7(17.5) |
33(82.5) |
40(100.0) |
|
|
|
| Total |
145(39.2) |
225(60.8) |
370(100.0) |
|
|
|
| Year of diagnosis |
|
|
|
|
|
|
| <1years |
6(24.0) |
19(76.0) |
25(100.0) |
|
|
|
| 1-5years |
131(41.6) |
184(58.4) |
315(100.0) |
5.15 |
2 |
0.0760 |
| >5year |
8(26.7) |
22(73.3) |
30(100.0) |
|
|
|
| Total |
|
|
|
|
|
|
| WHO Clinical Stage of disease |
| Stage I |
90(45.7) |
107(54.3) |
197(100.0) |
|
|
|
| Stage II |
52(35.9) |
93(64.1) |
145(100.0) |
13.69 |
2 |
0.0011 |
| Stage III |
3(10.7) |
25(89.3) |
28(100.0) |
|
|
|
| Year HAART was commenced |
| <1years |
9(33.3) |
18(66.7) |
27(100.0) |
|
|
|
| 1-5years |
127(43.3) |
166(56.7) |
293(100.0) |
|
|
|
| >5year |
4(16.0) |
21(84.0) |
25(100.0) |
7.78 |
2 |
0.0204 |
| Total |
140(40.6) |
205(59.4) |
345(100.0) |
|
|
|
| HAART |
| alluvia/truvada |
0(0.0) |
2(100.0) |
2(100.0) |
|
|
|
| Combipak |
99(38.8) |
156(61.2) |
255(100.0) |
|
|
|
| truv/nvp |
29(39.2) |
45(60.8) |
74(100.0) |
|
|
|
| Truvada/EFV |
8(66.7) |
4(33.3) |
12(100.0) |
|
|
|
| Zdv, 3TC,EFV |
0(0.0) |
2(100.0) |
2(100.0) |
6.5006 |
5 |
0.2605 |
| yet to start |
9(36.0) |
16(64.0) |
25(100.0) |
|
|
|
| Total |
145(39.2) |
225(60.8) |
370(100.0) |
|
|
|
PRESENT CD4
<200 |
8(9.8) |
74(90.2) |
82(100.2) |
|
|
|
| 200-349 |
28(31.1) |
62(68.9) |
90(100.0) |
|
|
|
| 350-499 |
48(51.6) |
45(48.4) |
93(100.0) |
22.21 |
2 |
0.00002 |
| ≥500 |
61(58.1) |
44(41.9) |
105(100.0) |
|
|
|
| Total |
145(39.2) |
225(60.8) |
370(100.0) |
|
|
|
|
